Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
Despite the phase II failure, Chemocentryx is pushing on in hidradenitis suppurativa.